Ketamine and Spravato Billing in 2026

The Codes That Pay, REMS Compliance and Why Off-Label Infusions Get Denied

By Team Rcmaxis  ·  October 20, 2026  ·  12 min read

Two drugs, same molecule, two completely different billing realities. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression, has its own HCPCS administration codes, and as of January 1, 2026 has a permanent drug code, J0013, replacing the temporary S0013 that Medicaid and commercial payers outside Medicare had used for years. IV ketamine infusion for depression is the same active ingredient's cousin, isn't FDA-approved for that use, has no dedicated administration code, and gets billed under a patchwork of workarounds that payers deny more often than they pay. If your clinic offers both, you're running two entirely different compliance postures under one roof.

Most denials on either side don't come from the drug being "not covered." They come from the claim not matching what the payer's system expects to see: the wrong code for a new patient, a missing REMS modifier, an infusion billed as if it were a routine IV visit instead of what it actually is. Fix the mismatch and a surprising number of claims that looked hopeless start paying.

Here's how the Spravato codes actually work, why ketamine infusion billing is so inconsistent, and what the one federal case involving a ketamine clinic's Medicare billing can teach you about where the real risk sits.

Spravato Billing: G2082, G2083 and the New J0013 Drug Code

Spravato's administration codes are dose-based, not time-based. HCPCS G2082 covers a treatment session using up to 56 mg of esketamine; G2083 covers a session above that dose. Both codes are restricted to established patients, so a new patient's first Spravato visit needs a separate billing approach for that initial encounter before G2082 or G2083 applies to follow-up sessions.

Here's where it gets payer-specific, and where a lot of clean claims go wrong: whether you can also bill a separate E/M code alongside G2082/G2083 depends entirely on the plan. Some Medicare Advantage guidance says to bill only G2082 or G2083 for the entire visit, drug and all; some commercial guidance expects the older drug code structure plus a separate E/M line. There's no single national answer, which means your intake process needs to capture payer type before the first Spravato session, not after the first denial.

REMS Compliance: The Modifier Most Practices Miss

Spravato is available only through the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which means both the prescriber and the dispensing healthcare setting have to be enrolled before the drug can be administered at all, independent of billing. Some payer guidance calls for a KX modifier on Medicare claims to confirm that REMS enrollment is active for both the prescriber and the site.

REMS enrollment isn't a one-time setup you forget about. If your facility relocates, adds a new prescriber, or changes its dispensing arrangement, the REMS enrollment has to follow that change, and a claim billed with the KX modifier while enrollment has lapsed is a compliance problem layered on top of a billing one. Confirm your specific MAC's or payer's current modifier requirement directly, since this isn't applied uniformly across every payer.

Why IV Ketamine Infusion for Depression Is a Different Billing Problem Entirely

Ketamine itself isn't FDA-approved for depression. Using IV ketamine that way is off-label, which doesn't make it illegal to prescribe, but it does mean there's no dedicated, universally accepted administration code the way Spravato has G2082 and G2083. Clinics commonly bill the infusion using standard IV administration codes (96365 and related add-on codes) while separately handling the drug cost, often as a self-pay item, because the drug itself frequently isn't a covered benefit for this indication.

Payer policy reinforces the gap. Aetna's published medical policy on ketamine for depression and related indications classifies the treatment as experimental, investigational or unproven, stating its clinical value and effectiveness haven't been established for that use. That kind of policy language means a claim coded perfectly will still deny on medical policy grounds with some payers, no matter how clean the paperwork is.

The bigger billing risk, though, isn't the coverage decision itself. Payer-side billing guidance and trade reporting both point to miscoding as the more common denial driver: billing the visit as a generic administrative encounter, or using an anesthesia code instead of the correct psychiatric administration code, obscures what service was actually performed and makes the claim look like something the plan has no reason to approve. Pair the administration code with the actual depression diagnosis code and the infusion details in the note, every time, even on claims you expect to get denied on medical policy grounds. A denial for medical policy is a clean, defensible outcome. A denial for miscoding invites a closer look at everything else on the claim.

What a Federal Ketamine Clinic Case Shows About the Real Risk

In January 2024, federal prosecutors indicted two Missouri physicians, Dr. Asim Muhammad Ali and Dr. Mohd Azfar Malik, on 22 felony counts tied to a psychiatric clinic that provided IV ketamine infusions, among other charges including conspiracy to commit health care fraud. The indictment alleges Dr. Ali billed Medicare using Dr. Malik's name and billing number without authorization for services, including annual wellness visits, not ketamine administration itself. These remain allegations, and the case hasn't been resolved in the sources available at this writing.

The lesson for a growing ketamine or Spravato practice isn't about the drug at all; it's about provider identity and billing number integrity. As more ketamine clinics take Medicare and Medicaid reimbursement, rather than running purely self-pay, they take on every federal health care fraud and abuse law that comes with it, including the Anti-Kickback Statute, the Stark Law and the False Claims Act, the same exposure any Medicare-participating practice carries. The specific mechanism in this case, billing under a provider identity that didn't actually render the service, is a basic control failure any practice can audit for internally before it becomes a federal indictment.

Build the Ketamine and Spravato Billing Workflow

Run Spravato and ketamine infusion as two separate billing tracks, even if the same clinical staff deliver both. Spravato's track centers on payer-specific code selection, REMS modifier accuracy, and new-vs-established patient logic. The ketamine infusion track centers on coding the administration correctly, documenting the depression diagnosis alongside it, and keeping the drug charge cleanly separated as self-pay where coverage doesn't exist.

Review denials from both tracks monthly, sorted by reason code, not just by dollar amount. A pattern of medical-policy denials on ketamine infusions is expected and not a red flag by itself. A pattern of miscoding or missing-modifier denials on either track is a process problem worth fixing before it becomes a bigger one.

• Keep a payer-specific Spravato code sheet. Update it whenever a plan changes its guidance.
• Verify REMS enrollment on a fixed schedule. Don't let a staffing change lapse it silently.
• Code ketamine infusions for what they are. Pair the administration code with the actual diagnosis every time.
• Audit rendering-provider accuracy quarterly. This is the exact control gap the one federal case on record exposed.

Our guide to psychiatry billing covers the broader behavioral health billing landscape these services sit inside, and our infusion therapy billing guide walks through the IV administration coding fundamentals that apply beyond ketamine specifically.

Frequently Asked Questions About Ketamine and Spravato Billing

What are the billing codes for Spravato (esketamine)?

HCPCS G2082 covers an esketamine administration session with a dose up to 56 mg, and G2083 covers a session above 56 mg. For the drug itself, Medicaid and commercial payers outside Medicare moved to the permanent HCPCS code J0013 on January 1, 2026, replacing the temporary code S0013. Medicare Advantage and commercial plans differ on whether separate E/M codes can be billed alongside G2082/G2083, so confirm the specific plan's policy before billing.

Is IV ketamine infusion for depression covered by insurance?

Often not. Ketamine isn't FDA-approved for depression; using it that way is off-label, and major payers, including Aetna's published medical policy, classify ketamine infusion for depression as experimental, investigational or unproven. Many practices bill the infusion drug as self-pay while billing the administration or monitoring visit to insurance, though whether the administration codes are payable when the drug itself isn't covered varies by payer and is often denied.

Do Spravato claims require a REMS modifier?

Spravato is dispensed only through the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, and for Medicare claims, some payer guidance calls for a KX modifier to confirm the prescriber and the dispensing healthcare setting are both enrolled in the Spravato REMS. Confirm your specific MAC's or payer's current requirement before submitting, since REMS modifier rules aren't universal across all payers.

Why do most ketamine and Spravato claims get denied?

For Spravato, most denials trace back to using the wrong code combination for the specific payer, new-patient billing on a code restricted to established patients, or a missing REMS modifier where one is required. For off-label IV ketamine infusions, payer guidance and trade reporting both point to miscoding, billing an administrative visit or anesthesia code instead of the correct psychiatric administration code, as a bigger cause of denials than the underlying coverage decision itself.